Table 1. Baseline characteristics.
| CBP (n = 63) | SDBP (n = 60) | SDBP-B (n = 63) | P value | |
| Age, mean ± SD | 64.7 ± 6.4 | 62.8 ± 7.2 | 63.2 ± 6.7 | 0.25 |
| Male sex, n (%) | 61 (96.8) | 59 (98.3) | 58 (92.1) | 0.19 |
| White race, n (%) | 41 (65.1) | 45 (75) | 51 (80.9) | 0.14 |
| Indication (FIT positive), n (%) | 52(82.5) | 44(73.3) | 48 (76.2) | 0.46 |
| DM Duration < 5 yr, n (%) | 23 (36.5) | 26 (43.3) | 24 (38.1) | 0.72 |
| Insulin use, n (%) | 23 (36.5) | 21 (35) | 24 (38.1) | 0.94 |
| HgbA1c mean ± SD | 7.3 ± 1.4 | 7.4 ± 1.8 | 7.4 ± 1.6 | 0.87 |
| Diabetic retinopathy, n (%) | 7 (11.1) | 7 (11.7) | 6 (9.5) | 0.92 |
| Diabetic nephropathy, n (%) | 2 (3.2) | 2 (3.3) | 3 (4.8) | 0.87 |
| Diabetic neuropathy, n (%) | 38 (60.3) | 39 (65) | 41 (65.1) | 0.81 |
| History of CAD, n (%) | 17 (26.9) | 23 (38.3) | 23 (36.5) | 0.36 |
| Cirrhosis, n (%) | 1 (1.6) | 4 (6.7) | 4 (6.4) | 0.33 |
| Stroke, n (%) | 3 (4.8) | 4 (6.7) | 6 (9.5) | 0.57 |
| Dementia, n (%) | 0 (0) | 1 (1.7) | 1 (1.6) | 0.59 |
| Narcotics use, n (%) | 21 (33.3) | 18 (30) | 24 (38.1) | 0.63 |
| CCB, n (%) | 19 (30.1) | 22 (36.7) | 23 (36.5) | 0.68 |
| TCA, n (%) | 3 (4.8) | 10 (16.7) | 3 (4.8) | 0.03 |
CBP, conventional bowel preparation; SDBP, split-dose bowel preparation; SDBP-B, split-dose bowel preparation plus bisacodyl; FIT, fecal immunochemical test; DM, diabetes mellitus; CCB, calcium channel blocker; TCA, tricyclic antidepressant; SD, standard deviation